Brokerages expect that Flexion Therapeutics, Inc. (NASDAQ:FLXN) will post earnings per share of ($0.95) for the current quarter, according to Zacks. Zero analysts have made estimates for Flexion Therapeutics’ earnings, with estimates ranging from ($1.02) to ($0.90). Flexion Therapeutics posted earnings of ($0.65) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 46.2%. The firm is scheduled to announce its next earnings results on Monday, November 6th.

On average, analysts expect that Flexion Therapeutics will report full year earnings of ($3.73) per share for the current year, with EPS estimates ranging from ($4.00) to ($3.44). For the next fiscal year, analysts expect that the company will post earnings of ($3.06) per share, with EPS estimates ranging from ($3.46) to ($2.50). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Flexion Therapeutics.

Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.11).

A number of equities research analysts have commented on FLXN shares. Cantor Fitzgerald set a $40.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a research note on Monday, May 22nd. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Janney Montgomery Scott reissued a “buy” rating and issued a $35.00 price objective (up previously from $30.00) on shares of Flexion Therapeutics in a research note on Wednesday, July 12th. Finally, Royal Bank Of Canada reissued a “buy” rating and issued a $44.00 price objective on shares of Flexion Therapeutics in a research note on Friday, July 7th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $31.50.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/15/0-95-earnings-per-share-expected-for-flexion-therapeutics-inc-flxn-this-quarter.html.

Several large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its position in shares of Flexion Therapeutics by 27.9% during the second quarter. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company’s stock valued at $54,921,000 after buying an additional 591,981 shares during the last quarter. Capital World Investors boosted its position in shares of Flexion Therapeutics by 2.0% during the second quarter. Capital World Investors now owns 2,538,000 shares of the specialty pharmaceutical company’s stock valued at $51,318,000 after buying an additional 49,000 shares during the last quarter. State Street Corp boosted its position in shares of Flexion Therapeutics by 66.3% during the second quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock valued at $27,888,000 after buying an additional 549,948 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Flexion Therapeutics by 5.9% during the second quarter. Vanguard Group Inc. now owns 1,054,464 shares of the specialty pharmaceutical company’s stock valued at $21,321,000 after buying an additional 59,143 shares during the last quarter. Finally, Wasatch Advisors Inc. boosted its position in shares of Flexion Therapeutics by 58.7% during the second quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock valued at $20,588,000 after buying an additional 376,745 shares during the last quarter. 82.75% of the stock is currently owned by institutional investors.

Flexion Therapeutics (FLXN) traded up 2.16% during midday trading on Friday, reaching $24.12. The company’s stock had a trading volume of 732,733 shares. The firm has a 50 day moving average of $23.24 and a 200 day moving average of $21.99. Flexion Therapeutics has a 52-week low of $15.88 and a 52-week high of $29.41. The firm’s market cap is $769.55 million.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.